Home > Inhibitors & Agonists

Inhibitors & Agonists

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DCC2934 Boc-phe-leu-glup(oph) 0
DCC2935 Km05382 CDK9 inhibitor, inhibiting transcription of GAPDH
DCC2936 km10340 Selective S1P3 agonist
DCC2937 Km-5-25 Novel inhibitor of the BfrB-Bfd complex, binding BfrB in the P. aeruginosa cytosol, blocking the BfrB-Bfd interaction and inhibiting iron mobilization from BfrB, resulting in cytosolic iron limitation that is manifested in a pyoverdine hyperproduction phe
DCC2938 Km-5-66 Novel inhibitor of the BfrB-Bfd complex, binding BfrB in the P. aeruginosa cytosol, blocking the BfrB-Bfd interaction and inhibiting iron mobilization from BfrB, resulting in cytosolic iron limitation that is manifested in a pyoverdine hyperproduction phe
DCC2939 kmi-1764 Novel BACE1 inhibitor with a non-acidic heterocycle at the P1' position
DCC2940 Kmn-010034 Novel Potent Hematopoietic Prostaglandin D2 Synthase (H-PGDS) Inhibitor
DCC2941 Kmn-80 Novel Potent and Selective EP4 Agonist
DCC2942 kms80013 Novel inhibitor of amyloid-
DCC2943 Kms88009 Novel inhibitor of amyloid-β aggregation, ameliorating the neurodegenerative disorder
DCC2944 Kmup-3 Novel enhancer of cGMP activity; Aortic smooth muscle relaxant
DCC2945 Kmup-4 Novel enhancer of cGMP activity; Aortic smooth muscle relaxant
DCC2946 Kongensin D Natural anti-TNBC agent, significantly suppressing the triple-negative breast cancer (TNBC) tumor growth without causing side effects
DCC2947 kp1212 Novel non-chain terminating nucleoside analog anti-HIV inhibitor
DCC2948 Kpt-6604 Novel selective, orally bioavailable, PAK4 allosteric modulator against triple negative breast cancer
DCC2949 Kpu-300 Novel potent antimicrotubule agent, exhibiting potent cytotoxicity against HT-29 cells by strongly binding to tubulin and inducing microtubule depolymn.
DCC2950 Kr-12-a4 Potent antimicrobial peptide against gram-positive and gram-negative bacteria and relatively high LPS-neutralization activity
DCC2951 Kr-25210 Novel enteroviral replication inhibitor through a non-capsid binding mode with EC 50 values of 2.5, 2.2, and 3.7 μM against hRV B14, A21, and A71, respectively, targeting the replication stages in the virus
DCC2952 Kr-31762 Novel KATP channel opener, exerting cardioprotective effects by opening SarcKATP channels in rat models of ischemia/reperfusion-induced heart injury
DCC2953 Kras(g12c)-in-1 Novel irreversible inhibitor of KRAS(G12C)
DCC2954 Kras4b-in-d14 Novel specific inhibitor of oncogenic KRAS4b signaling, stabilizing the KRAS4b-PDEδ complex and remarkably decreasing tumor size and triggered apoptosis of tumor cells
DCC2955 Kras4b-pdeδ Stabilizer C19 Novel stabilizer of the KRAS4b-PDEδ complex, decreasing the proliferation of colorectal cancer cells, and increasing apoptosis via decreased activation of oncogenic KRAS4b signaling
DCC2956 Krc-108 Novel potent multi-kinase inhibitor, targeting Ron, Flt3 and TrkA as well as c-Met
DCC2957 Krc-327 Selective novel inhibitor of c-Met receptor tyrosine kinase with anticancer activity.
DCC2958 Krm-ii-08 Novel potent, non-toxic, blood-brain barrier crossing, α5-GABA A R preferring ligand, enhancing a chloride-anion efflux that induces mitochondrial membrane depolarization and in response, TP53 upregulation and p53, constitutively phosphorylated at S392, c
DCC2959 Krn4884 Potassium channel opener
DCC2960 Krn-8602 Hydrochloride Topo II inhibitor, exhibiting cytotoxic effects against tumour cells
DCC2961 Krp-109 Novel neutrophil elastase (NE) inhibitor, decreasing expression of TGF-ß Signal Related Genes
DCC2962 Krp-199 Highly potent and selective antagonist for the AMPA receptors, exhibiting good neuroprotective effects in vivo
DCC2963 Krp-204 Novel highly selective β3-adrenoceptor agonist being developed for the treatment of diabetes and obesity

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X
>